@article{e212315a3d29492dab624eced9956b53,
title = "Comment on: Perspective: A Caveat About Financial Incentives for Anti−vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy",
author = "VANDER, \{JAMES F.\} and FINEMAN, \{MITCHELL S.\} and SUNIR GARG and REGILLO, \{CARL D.\}",
note = "Funding Information: Funding: None. Financial Disclosures: S.G.: Research grant support: American Academy of Ophthalmology, Apellis, Boehringer Ingelheim, NGM Bio, Regeneron Consultant: Allergan, Apellis, Bausch + Lomb, Boehringer Ingelheim, Johnson \& Johnson, Kanaph, Merck Manuals. C.D.R.: Research grant support: Adverum, Allergan, Annexon, Apellis, Astellis, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Ocugen, Opthea, Regeneron, RegenXBio. Consulting: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Clearside, Eyepoint, Genentech, Graybug, Iveric, Janssen, Kodiac, Lineage, Merck, NGM, Novartis, Ocugen, Opthea, RegenXBio, Stealth, Thea, Zeiss. No other authors report financial disclosures. Conflict of Interest: None. Acknowledgments: None.",
year = "2023",
month = jun,
doi = "10.1016/j.ajo.2023.01.029",
language = "English",
volume = "250",
pages = "186--187",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier Inc.",
}